PMID- 31077149 OWN - NLM STAT- MEDLINE DCOM- 20200318 LR - 20200318 IS - 1471-2261 (Electronic) IS - 1471-2261 (Linking) VI - 19 IP - 1 DP - 2019 May 10 TI - Significant association between admission serum monocyte chemoattractant protein-1 and early changes in myocardial function in patients with first ST-segment elevation myocardial infarction after primary percutaneous coronary intervention. PG - 107 LID - 10.1186/s12872-019-1098-z [doi] LID - 107 AB - BACKGROUND: Recent studies have indicated that monocyte chemoattractant protein-1 (MCP-1) plays an important role in the initiation and progression of ischaemic heart disease. However, no previous research has investigated the correlation between serum MCP-1 levels and early changes in myocardial function in patients with ST-segmental elevation myocardial infarction (STEMI) after primary percutaneous coronary intervention (PCI). METHODS: A total of 87 STEMI patients who had undergone a successful primary PCI were consecutively recruited. All the patients included in this study were grouped into two subgroups according to the median value of MCP-1 upon admission. An early change in left ventricular ejection fraction (LVEF) was defined as (LVEF at 3 months post-STEMI)-(LVEF at 2 days post-STEMI). RESULTS: Serum MCP-1 levels increased gradually over time during the first 72 h after the onset of STEMI. The concentration of hypersensitive cardiac troponin I (hs-cTnI) upon admission as well as at 24 h and 72 h after primary PCI, especially the peak hs-cTnI concentration, declined significantly in the low admission MCP-1 group. As continuous variable, admission MCP-1 also correlated positively with admission hs-cTnI, hs-cTnI at 24 h after primary PCI, and peak hs-cTnI. Additionally, the absolute early change in LVEF improved markedly in the low admission MCP-1 group (3.77% +/- 6.05% vs - 0.18% +/- 7.69%, p = 0.009) compared to that in the high admission MCP-1 group. Most importantly, the global LVEF in the low admission MCP-1 group also improved significantly at 3 months compared to baseline LVEF (55.79% +/- 7.05% vs 59.60% +/- 6.51%, p = 0.011), while an improvement in global LVEF was not observed in the high admission MCP-1 group. Furthermore, as a continuous variable, the MCP-1 level up admission also correlated negatively with early changes in LVEF (r = - 0.391, p = 0.001). After assessment by multiple linear regression analysis, the MCP-1 level upon admission remained correlated with early changes in LVEF [beta = - 0.089, 95% CI (- 0.163 to - 0.015), p = 0.020]. CONCLUSION: MCP-1 upon admission not only correlated positively with hs-cTnI at different time points and peak hs-cTnI, but also associated inversely with early improvements in myocardial function in patients with first STEMI. So we speculated that suppression the expression of MCP-1 via various ways may be a promising therapeutic target in myocardial I/R injury in the future. FAU - Zhu, Yong AU - Zhu Y AD - Department of cardiology, Beijing Anzhen Hospital, Capital Medical University, #2, Anzhenlu, Chaoyang District, Beijing, 100029, China. FAU - Hu, Chengping AU - Hu C AD - Department of cardiology, Beijing Anzhen Hospital, Capital Medical University, #2, Anzhenlu, Chaoyang District, Beijing, 100029, China. FAU - Du, Yu AU - Du Y AD - Department of cardiology, Beijing Anzhen Hospital, Capital Medical University, #2, Anzhenlu, Chaoyang District, Beijing, 100029, China. FAU - Zhang, Jianwei AU - Zhang J AD - Department of cardiology, Beijing Anzhen Hospital, Capital Medical University, #2, Anzhenlu, Chaoyang District, Beijing, 100029, China. FAU - Liu, Jinxing AU - Liu J AD - Department of cardiology, Beijing Anzhen Hospital, Capital Medical University, #2, Anzhenlu, Chaoyang District, Beijing, 100029, China. FAU - Han, Hongya AU - Han H AD - Department of cardiology, Beijing Anzhen Hospital, Capital Medical University, #2, Anzhenlu, Chaoyang District, Beijing, 100029, China. FAU - Zhao, Yingxin AU - Zhao Y AUID- ORCID: 0000-0002-4897-2779 AD - Department of cardiology, Beijing Anzhen Hospital, Capital Medical University, #2, Anzhenlu, Chaoyang District, Beijing, 100029, China. zyingxinmi@163.com. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20190510 PL - England TA - BMC Cardiovasc Disord JT - BMC cardiovascular disorders JID - 100968539 RN - 0 (Biomarkers) RN - 0 (CCL2 protein, human) RN - 0 (Chemokine CCL2) SB - IM MH - Adult MH - Aged MH - Beijing MH - Biomarkers/blood MH - Chemokine CCL2/*blood MH - Cross-Sectional Studies MH - Humans MH - Middle Aged MH - *Patient Admission MH - *Percutaneous Coronary Intervention MH - Recovery of Function MH - ST Elevation Myocardial Infarction/blood/diagnosis/physiopathology/*therapy MH - *Stroke Volume MH - Time Factors MH - Treatment Outcome MH - Up-Regulation MH - *Ventricular Function, Left PMC - PMC6511179 OTO - NOTNLM OT - Hs-cTnI OT - I/R injury OT - LVEF OT - MCP-1 OT - STEMI COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Before initiation of the present study, we obtained approval from the ethics committee of Beijing Anzhen Hospital, Beijing Da Xing Hospital, Capital Medical University. In addition, we also obtained informed written consent from the recruited patients. CONSENT FOR PUBLICATION: Not applicable COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2019/05/12 06:00 MHDA- 2020/03/19 06:00 PMCR- 2019/05/10 CRDT- 2019/05/12 06:00 PHST- 2018/12/11 00:00 [received] PHST- 2019/05/03 00:00 [accepted] PHST- 2019/05/12 06:00 [entrez] PHST- 2019/05/12 06:00 [pubmed] PHST- 2020/03/19 06:00 [medline] PHST- 2019/05/10 00:00 [pmc-release] AID - 10.1186/s12872-019-1098-z [pii] AID - 1098 [pii] AID - 10.1186/s12872-019-1098-z [doi] PST - epublish SO - BMC Cardiovasc Disord. 2019 May 10;19(1):107. doi: 10.1186/s12872-019-1098-z.